Inebilizumab targets and depletes CD19+ B cells and may be effective for treating patients with IgG4-related disease. In this phase 3, multicenter, double-blind, randomized, placebo-controlled ...

Discover how inebilizumab reduces flares and improves remission rates in IgG4-related disease in this phase 3 clinical trial.

An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

IgG4-related disease (IgG4-RD) is a rare autoimmune disease. A study published in The New England Journal of Medicine by the ...

Discover a trial that included 135 adults, randomly assigned to receive either inebilizumab or a placebo for a 52-week ...

Flare-free, treatment-free complete remission and flare-free, glucocorticoid-free complete remission occurred in more participants in the inebilizumab group than the placebo group. (HealthDay News ...

For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...

So this is super exciting and does speak to the ability not only that inebilizumab is clinically beneficial, but also that we can actually successfully reduce the burden of corticosteroids in our ...

The study, published in the New England Journal of Medicine, found that treatment with inebilizumab greatly reduced the symptoms of immunoglobulin G4–related disease (IgG4-RD), compared to placebo.

today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) for the treatment of adults with ...